Clinical trials: Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart Failure With Preserved Ejection Fraction
Finerenone and Cardiac Remodeling in HFpEF
This prospective randomized study aims to evaluate the efficacy of Finerenone as add-on therapy to standard of care compared to standard of care alone in preventing heart failure worsening and preserving cardiac function assessed…
- Trial name
- NCT07830940
- Testing
- Finerenone, Standard of care for HFpEF Description:
- Volunteers
- 194 people
- Sponsor
- Assiut University
Heart Failure With Preserved Ejection Fraction
Matching Perfusion and Metabolic Activity in HFpEF
This study will test whether pharmacologic agents that increase perfusion [Potassium Nitrate (KNO3)], with and without additional supplements that may improve mitochondrial function [Propionyl-L-Carnitine (PLC) and Nicotinamide…
- Trial name
- MPMA (NCT04913805)
- Testing
- Potassium Nitrate, Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside, Potassium Chloride
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Pennsylvania
Heart Failure
Inspiratory Muscle Training in HFpEF
This study is being done to determine how inspiratory muscle training impacts inspiratory muscle function during exercise in heart failure patients.
- Trial name
- NCT06510231
- Testing
- Inspiratory Muscle Training
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Mayo Clinic
Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers
This study is randomized, single-blind, placebo-controlled Phase 1 study aimed to assess the safety and efficacy, pharmacokinetics and pharmacodynamics of multiple doses of oral AZD4831 in healthy Japanese and Chinese volunteers
- Trial name
- NCT04232345
- Testing
- AZD4831
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure With Preserved Ejection Fraction, Cardiovascular Morbidity
Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF
Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of…
- Trial name
- ARTSPREDICTION (NCT06208007)
- Where
- Germany
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University Medical Center Goettingen
Heart Failure, Heart Failure, Diastolic
RESPONDER-HF Trial
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
- Trial name
- NCT05425459
- Testing
- Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 750 people
- Sponsor
- Corvia Medical
Hypertension, Pulmonary
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
- Trial name
- CADENCE (NCT04945460)
- Testing
- Sotatercept 0.3 mg/kg, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Where
- 119 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Heart Failure With Preserved Ejection Fraction
Diastolic Exercise Stress Testing in Heart Failure
Patients with an intermediate risk (HFA-PEFF score 2-4 points) for heart failure with preserved ejection fraction (HFpEF) will be further investigated with invasive right heart catheterization.
- Trial name
- DEST-HF (NCT04970953)
- Testing
- Right heart catheterization
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- University Hospital, Essen
Heart Failure
Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
- Trial name
- NCT03611153
- Testing
- AZD4831 Oral Myeloperoxidase Inhibitor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Cardiac Failure
The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
This randomised, double-blind, placebo-controlled, phase 2 study aims to evaluate the efficacy and safety of the anti-fibrotic drug pirfenidone in the treatment of patients with heart failure and preserved left ventricular…
- Trial name
- PIROUETTE (NCT02932566)
- Testing
- Pirfenidone
- Where
- United Kingdom
- Volunteers
- 129 people
- Sponsor
- Manchester University NHS Foundation Trust
Heart Failure, Diastolic, Heart Failure, Systolic
Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Heart failure (HF) is a syndrome, resulting from structural or functional impairment of ventricular filling or ejection of blood.
- Conditions
- Heart Failure, Diastolic, Heart Failure, Systolic, Pulmonary Hypertension, Atrial Fibrillation
- Trial name
- PRESMET (NCT05475028)
- Testing
- RRBS
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension
Exercise Right Ventricular Coupling in HFpEF
The investigators aim to evaluate the feasibility and prognostic value of right ventricular-arterial coupling (RVAC) during exercise in patients with HFpEF-PH using a hybrid technique of real-time CMRderived volume measures and…
- Trial name
- ENDURE (NCT05731466)
- Testing
- CardioMems HF System
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
HFpEF - Heart Failure With Preserved Ejection Fraction, Cardiac Catheterisation
Can Tiny Bubbles Offer an Alternative to Catheters for Assessing Pressures Inside the Heart? Investigating Ultrasound Contrast Agents as Pressure Sensors Against Gold Standard Catheter Pressures in Cardiac Catheterisation Patients.
The goal of this clinical trial is to investigate if ultrasound contrast agents can be used to estimate filling pressures inside the heart in patients with suspected heart disease.
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, Cardiac Catheterisation, Heart Disease
- Trial name
- SonoHeart (NCT07416279)
- Testing
- Contrast Echocardiography
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- King's College London
Heart Failure, Diastolic, Multicenter Study
Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging
The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are…
- Trial name
- NCT04602338
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Validation of a Machine Learning Predictive Model to Distinguish Post-capillary Pulmonary Hypertension
In this study the diagnostic accuracy of a diagnostic tool for the diagnosis of post-capillary pulmonary hypertension will be investigated.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- Optiek 2-0 (NCT06405126)
- Testing
- Optiek predictive model
- Where
- 4 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- KU Leuven
Heart Failure, Preserved Ejection Fraction
Precision Rehabilitation for Veterans With (HFpEF)
This study is being completed because there is conflicting information regarding the value of monitored exercise in patients with heart failure with preserved ejection fraction (HFpEF).
- Trial name
- NCT07493915
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia VA Health Care System
Heart Failure With Preserved Ejection Fraction, Chronotropic Incompetence
Effects of a Supervised Training Program on Functional Capacity in Patients With HFpEF and Chronotropic Incompetence
This is a prospective study, blinded for the evaluator, randomized (1:1:1:1) to receive standard management alone or combined with a program of training (aerobic alone or combined with strength exercises) that will be carried out…
- Trial name
- Training-HR (NCT05649787)
- Testing
- Supervised aerobic training, Supervised aerobic plus low to moderate-intensity strength training, Supervised aerobic plus moderate to high-intensity strength training
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Diastolic Heart Failure NYHA Class III-IV, Diastolic Dysfunction Secondary to Aortic Stenosis
CORolla™ TAA for Heart Failure and Preserved Ejection Fraction and Diastolic Dysfunction
The study purpose is to evaluate the safety and feasibility of the CORolla™ TAA in two treatment groups, "CORolla™ Stand-alone group" and " AVR \& CORolla™ Add on group".
- Trial name
- NCT01956526
- Testing
- CORolla™ TAA device
- Where
- 2 sites in Italy
- Volunteers
- 12 people
- Sponsor
- CorAssist Cadiovascular Ltd.
Heart Failure With Preserved Ejection Fraction
Dapagliflozin With or Without Spironolactone for HFpEF
Heart failure (HF) is a condition in which the heart does not contract ("pump") or relax well, leading to insufficient perfusion of vital organs.
- Trial name
- SOGALDI-PEF (NCT05676684)
- Testing
- Dapagliflozin, Spironolactone + Dapagliflozin
- Where
- 2 sites in Portugal
- Volunteers
- 108 people
- Sponsor
- Universidade do Porto
Heart Failure With Normal Ejection Fraction
Treatment of HFpEF With Nitrate Supplement
The objective of this project is to determine if Neo40, a nitric oxide generating lozenge, when consumed twice daily by subjects with HFpEF, will increase exercise tolerance, decrease symptoms and improve quality of life for…
- Trial name
- NCT03289481
- Testing
- Active lozenge
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- MaineHealth